An overview of the mTOR pathway as a target in cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 5, 2012, Pages 481-489

  Gentzler, Ryan D ^a   Altman, Jessica K ^a,b   Platanias, Leonidas C ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

AKT; Breast cancer; Everolimus; Leukemia; Lymphoma; MTOR; PI3K; PTEN; Rapamycin; Renal cell carcinoma; Ridaforolimus; Sarcoma; Sirolimus; Temsirolimus; TORC1; TORC2

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; AROMATASE INHIBITOR; AZD 8055; DASATINIB; EVEROLIMUS; EXEMESTANE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NILOTINIB; OSI 027; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER INHIBITION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; HUMAN; KIDNEY CARCINOMA; LEUKEMIA; LYMPHOMA; MANTLE CELL LYMPHOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NEOPLASM; NEUROENDOCRINE TUMOR; NONHUMAN; OVERALL SURVIVAL; PROTEIN FUNCTION; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84860250827     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2012.677439     Document Type: Review

References (88)

1. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 1975;28:721-726
2. Huang S, Bjornsti MA, Houghton PJ. Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2003;2:222-232
3. Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev 1981;8:63-87
4. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-Arresting rapamycin-receptor complex. Nature 1994;369:756-758
5. Mamane Y, Petroulakis E, LeBacquer O, et al. mTOR, translation initiation and cancer. Oncogene 2006;25:6416-6422
6. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18:1926-1945
7. Chen J, Zheng XF, Brown EJ, et al. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-Associated protein and characterization of a critical serine residue. Proc. Natl. Acad. Sci. USA 1995;92:4947-4951
8. Fang Y, Vilella-Bach M, Bachmann R, et al. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001;294:1942-1945
9. Toschi A, Lee E, Xu L, et al. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: Competition with rapamycin. Mol Cell Biol 2009;29:1411-1420
10. Chen Y, Zheng Y, Foster DA. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 2003;22:3937-3942
11. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011;23:744-755
12. Petroulakis E, Mamane Y, Le Bacquer O, et al. mTOR signaling: Implications for cancer and anticancer therapy. Br J Cancer 2006;94:195-199
13. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 2009;27(Suppl 2):S43-51
14. Altman JK, Sassano A, Platanias LC. Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2011;2:510-517
15. Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8:187-198
16. Sabatini DM. mTOR and cancer: Insights into a complex relationship. Nat Rev Cancer 2006;6:729-734
17. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007;12:487-402
18. Khokhar NZ, Altman JK, Platanias LC. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies. Curr Opin Oncol 2011;23:578-586
19. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-5510
20. Calera MR, Martinez C, Liu H, et al. Insulin increases the association of Akt-2 with Glut4-containing vesicles. J Biol Chem 1998;273:7201-7204
21. Majumder PK, Febbo PG, Bikoff R, et al. Mtor inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-501
22. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913-963
23. Gingras AC, Gygi SP, Raught B, et al. Regulation of 4E-BP1 phosphorylation: A novel two-step mechanism. Genes Dev 1999;13:1422-1437
24. Holz MK, Ballif BA, Gygi SP, et al. Mtor and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 2005;123:569-580
25. Zinzalla V, Stracka D, Oppliger W, et al. Activation of MtorC2 by association with the ribosome. Cell 2011;144:757-768
26. Altman JK, Platanias LC. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol 2008;15:88-94
27. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits MtorC2 assembly and Akt/PKB. Mol Cell 2006;22:159-168
28. Carayol N, Vakana E, Sassano A, et al. Critical roles for MtorC2- and rapamycin-insensitive MtorC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc. Natl. Acad. Sci. USA 2010;107:12469-74
29. Altman JK, Sassano A, Kaur S, et al. Dual MtorC2/MtorC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res 2011;17:4378-4388
30. Janes MR, Limon JJ, So L, et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010;16:205-213
31. Sato T, Nakashima A, Guo L, et al. Single amino-Acid changes that confer constitutive activation of Mtor are discovered in human cancer. Oncogene 2010;29:2746-2752
32. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer cell 2003;4:257-262
33. Sanchez-Cespedes M. The role of LKB1 in lung cancer. Fam Cancer 2011;10:447-453
34. van Slegtenhorst M, De Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997;277:805-808
35. Benjamin D, Colombi M, Moroni C, et al. Rapamycin passes the torch: A new generation of Mtor inhibitors. Nat Rev Drug Discov 2011;10:868-880
36. Thoreen CC, Kang SA, Chang JW, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of MtorC1. J Biol Chem 2009;284:8023-8032
37. Yellen P, Saqcena M, Salloum D, et al. High-dose rapamycin induces apoptosis in human cancer cells by dissociating Mtor complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011;10:3948-3956
38. Chiang GG, Abraham RT. Targeting the Mtor signaling network in cancer. Trends Mol Med 2007;13:433-442
39. O'Reilly KE, Rojo F, She QB, et al. Mtor inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508
40. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-7058
41. Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-1863
42. Willems L, Chapuis N, Puissant A, et al. The dual MtorC1 and MtorC2 inhibitor AZD8055 has anti-Tumor activity in acute myeloid leukemia. Leuk 2011; Epub ahead of print.
43. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-3829
44. Parekh S, Weniger MA, Wiestner A. New molecular targets in mantle cell lymphoma. Semi Cancer Biol 2011;21:335-346
45. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: Perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750-762
46. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-Agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23:5347-5356
47. Gupta M, Wahner Hendrickson AE, Yun SS, et al. Dual MtorC1/MtorC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 2012;119:476-487
48. Castillo JJ, Furman M, Winer ES. CAL-101: A phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 2012;21:15-22
49. Furman RR, Byrd JC, Brown JR, et al. CAL-101, An isoform-selective inhibitor of Phosphatidylinositol 3-Kinase P110, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. ASH Annu Meeting Abstr 2010;116:55
50. Kahl B, Byrd JC, Flinn IW, et al. Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110-delta, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. ASH Annu Meeting Abstr 2010;116:1777
51. Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005;105:2527-2534
52. Xu Q, Simpson SE, Scialla TJ, et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003;102:972-980
53. Stirewalt DL, Radich JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003;3:650-665
54. Chen W, Drakos E, Grammatikakis I, et al. Mtor signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol Cancer 2010;9:292
55. Callera F, Lopes CO, Rosa ES, et al. Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome. Leuk Res 2008;32:1633-1634
56. Tamburini J, Chapuis N, Bardet V, et al. Mammalian target of rapamycin (Mtor) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: Rationale for therapeutic inhibition of both pathways. Blood 2008;111:379-382
57. Chiarini F, Fala F, Tazzari PL, et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res 2009;69:3520-3528
58. Kharas MG, Janes MR, Scarfone VM, et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/Mtor inhibitor prevents expansion of human BCR-ABL+ leukemia cells. J Clin Invest 2008;118:3038-3050
59. Kojima K, Shimanuki M, Shikami M, et al. The dual PI3 kinase/Mtor inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-Type AML. Leukemia 2008;22:1728-1736
60. Park S, Chapuis N, Bardet V, et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and Mtor, has antileukemic activity in AML. Leukemia 2008;22:1698-1706
61. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-3356
62. Redig AJ, Vakana E, Platanias LC. Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL. Leuk Lymphoma 2011;52(Suppl 1):45-53
63. Cilloni D, Saglio G. Molecular Pathways: BCR-ABL. Clin Cancer Res 2012;18:930-937
64. Fullmer A, Kantarjian H, Cortes J, et al. New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Leuk Lymphoma 2011;52(Suppl 1):81-91
65. Diamond JM, Melo JV. Mechanisms of resistance to BCR-ABL kinase inhibitors. Leuk Lymphoma 2011;52(Suppl 1):12-22
66. Hochhaus A, La Rosee P, Muller MC, et al. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia. Cell Cycle 2011;10:250-260
67. Cortes J, Hochhaus A, Hughes T, et al. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J Clin Oncol 2011;29:524-531
68. Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011;25:7-22
69. Sillaber C, Mayerhofer M, Bohm A, et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 2008;38:43-52
70. Vakana E, Sassano A, Platanias LC. Induction of autophagy by dual MtorC1-MtorC2 inhibition in BCR-ABL-expressing leukemic cells. Autophagy 2010;6:966-967
71. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 2007;356:185-187
72. Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83
73. Toschi A, Lee E, Gadir N, et al. Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on MtorC1 and MtorC2. J Biol Chem 2008;283:34495-9
74. Voss MH, Molina AM, Motzer RJ. Mtor inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011;25:835-852
75. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281
76. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456
77. Cho DC, Atkins MB. Future directions in renal cell carcinoma: 2011 and beyond. Hematol Oncol Clin North Am 2011;25:917-935
78. Carew JS, Kelly KR, Nawrocki ST. Mechanisms of Mtor inhibitor resistance in cancer therapy. Target Oncol 2011;6:17-27
79. Cho DC, Cohen MB, Panka DJ, et al. The efficacy of the novel dual PI3-kinase/Mtor inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin Cancer Res 2010;16:3628-3638
80. Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003;3:685-694
81. Okuno S, Bailey H, Mahoney MR, et al. A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: A study of the Mayo phase 2 consortium (P2C). Cancer 2011;117:3468-3475
82. Chawla SP, Staddon AP, Baker LH, et al. Phase II Study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. Journal of clinical oncology. Am Soc Clin Oncol 2012;30:78-84
83. Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Eval. of the Efficacy of Ridaforolimus) [NCT00538239]. Available from: Http://clinicaltrials.gov/ct2/show/NCT00538239 [Cited 1 January 2012]
84. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol 2011;29:4452-4461
85. Baselga J, Campone M, Piccart M, et al. Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2012;366:520-529
86. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: Expression profiling evidences a role for AKT-Mtor pathway. Am Soc of Clin Oncol 2010;28:245-255
87. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and Mtor pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331:1199-1203
88. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523